Inhibition of the ZEB1–BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma
Abstract
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive tumour from the biliary tree that is characterized by a prominent desmoplastic stroma, mainly composed of cancer-associated fibroblasts (CAF), and a poor prognosis due to its late clinical presentation and the lack of effective non-surgical treatments. Current therapies still include chemotherapeutic combinations of gemcitabine and cisplatin for the majority of the patients showing poor results due the apparition of resistance. This situation led us to interrogate the potential role in the development of chemoresistance of ZEB1, an EMT-inducing transcription factor (EMT-TF) that we previously identified as a pro-tumorigenic factor in tumour cells and CAF of iCCA. By analysing human CCA samples and sc-RNAseq public databases, we show here that ZEB1 is present in the tumour microenvironment of all iCCA patients tested and is prominently expressed by the myofibroblastic CAF subpopulation (myCAF). Using cellular models of CAF, we show that cells depleted for ZEB1 are more sensitive to gemcitabine and cisplatin, via a mechanism involving the direct regulation of the anti-apoptotic gene BCL2. Moreover, ZEB1 expressing CAF protect iCCA tumour cells against the toxicity of the chemotherapeutic drugs through the release of paracrine soluble factors, including CTGF, IL6 and IL8, an event that could be reversed by the BCL2 inhibitor venetoclax. Therefore, our results point to the use of BCL2 inhibitors as a way to improve the efficacy of current chemotherapeutic regimens in iCCA patients.
Related
- Case Report: Klebsiella pneumoniae-associated pyogenic spondylitis and occult intrahepatic cholangiocarcinoma during calculous cholangitis.
- PBRM1 knockdown is associated with NRF2-dependent ALDOA upregulation and metabolic reprogramming in HCCC-9810 intrahepatic cholangiocarcinoma cells
- Genomic and immune profiling characterizes immune heterogeneity and a TIGIT-associated subtype in intrahepatic cholangiocarcinoma.
- Synchronous hepatocellular carcinoma and IPNB-associated intrahepatic cholangiocarcinoma in a patient with resolved viral hepatitis: a case report of diagnostic pitfall and margin-negative resection
- Number of examined lymph nodes and overall survival in intrahepatic cholangiocarcinoma: a population-based study suggesting a staging benefit
BibTeX
@article{gonzalezsanchez2026inhibition,
title = {{Inhibition of the ZEB1–BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma}},
author = {Ester Gonzalez-Sanchez and Marie Vallette and Lucia Garcia-Collado and Aashreya Ravichandra and Mirko Minini and Allan Pavy and Josep Amengual and Carlos Andres Roldán-Hernández and Ana Martin Ramirez and Corentin Louis and Juan Jose Lozano and Isabel Fabregat and Nathalie Guedj and Valérie Paradis and Cedric Coulouarn and Lynda Aoudjehane and Laura Fouassier and Javier Vaquero},
journal = {Biomedicine and Pharmacotherapy},
year = {2026},
month = jul,
doi = {10.1016/j.biopha.2026.119741},
url = {https://hal.science/hal-05684367v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Inhibition of the ZEB1–BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma
AU - Ester Gonzalez-Sanchez
AU - Marie Vallette
AU - Lucia Garcia-Collado
AU - Aashreya Ravichandra
AU - Mirko Minini
AU - Allan Pavy
AU - Josep Amengual
AU - Carlos Andres Roldán-Hernández
AU - Ana Martin Ramirez
AU - Corentin Louis
AU - Juan Jose Lozano
AU - Isabel Fabregat
AU - Nathalie Guedj
AU - Valérie Paradis
AU - Cedric Coulouarn
AU - Lynda Aoudjehane
AU - Laura Fouassier
AU - Javier Vaquero
PY - 2026
DA - 2026/07/06
JO - Biomedicine and Pharmacotherapy
DO - 10.1016/j.biopha.2026.119741
UR - https://hal.science/hal-05684367v1
AB - Intrahepatic cholangiocarcinoma (iCCA) is an aggressive tumour from the biliary tree that is characterized by a prominent desmoplastic stroma, mainly composed of cancer-associated fibroblasts (CAF), and a poor prognosis due to its late clinical presentation and the lack of effective non-surgical treatments. Current therapies still include chemotherapeutic combinations of gemcitabine and cisplatin for the majority of the patients showing poor results due the apparition of resistance. This situation led us to interrogate the potential role in the development of chemoresistance of ZEB1, an EMT-inducing transcription factor (EMT-TF) that we previously identified as a pro-tumorigenic factor in tumour cells and CAF of iCCA. By analysing human CCA samples and sc-RNAseq public databases, we show here that ZEB1 is present in the tumour microenvironment of all iCCA patients tested and is prominently expressed by the myofibroblastic CAF subpopulation (myCAF). Using cellular models of CAF, we show that cells depleted for ZEB1 are more sensitive to gemcitabine and cisplatin, via a mechanism involving the direct regulation of the anti-apoptotic gene BCL2. Moreover, ZEB1 expressing CAF protect iCCA tumour cells against the toxicity of the chemotherapeutic drugs through the release of paracrine soluble factors, including CTGF, IL6 and IL8, an event that could be reversed by the BCL2 inhibitor venetoclax. Therefore, our results point to the use of BCL2 inhibitors as a way to improve the efficacy of current chemotherapeutic regimens in iCCA patients.
SN - 0753-3322
SN - 1950-6007
ER -